Investor Relations

Press Releases

Date Title and Summary View
Toggle Summary NanoString Technologies Introduces nCounter Elements™ Reagents to Support Needs of Translational Research and Clinical Laboratory Testing
nCounter Elements General Purpose Reagents are First NanoString Product with Open Architecture to Support Independent Development of Diagnostic Tests SEATTLE & HOUSTON --(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and
View HTML
Toggle Summary NanoString Technologies to Release Second Quarter 2013 Financial Results and Host Conference Call on Tuesday, August 6, 2013
SEATTLE , July 17, 2013 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company will release 2013 second quarter financial results after the close of trading on
View HTML
Toggle Summary Study Published in The Journal of Clinical Oncology Demonstrates Advantages of NanoString's ProsignaTM Breast Cancer Assay
Authors Conclude that PAM50-based Assay Provides More Prognostic Information than Oncotype DX ® with Better Differentiation of Intermediate and High Risk Groups SEATTLE --(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and
View HTML
Toggle Summary NanoString Technologies Prices Initial Public Offering
NanoString Technologies Prices Initial Public Offering SEATTLE--(BUSINESS WIRE)--June 25, 2013-- NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced the pricing of its initial public offering of 5.4 million
View HTML
Toggle Summary Results of New Analysis Support Use of NanoString's Prosigna™ Assay to Help Identify Node-Positive Early-Stage Breast Cancer Patients at Low Risk of Recurrence
Study Segments Breast Cancer Patients According to Tumor Genomics and Number of Positive Nodes
View HTML
Toggle Summary NANOSTRING TECHNOLOGIES FILES REGISTRATION STATEMENT WITH THE SECURITIES AND EXCHANGE COMMISSION FOR AN INITIAL PUBLIC OFFERING
NANOSTRING TECHNOLOGIES FILES REGISTRATION STATEMENT WITH THE SECURITIES AND EXCHANGE COMMISSION FOR AN INITIAL PUBLIC OFFERING   SEATTLE | May 20, 2013 – NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced
View HTML
Toggle Summary NanoString Technologies Announces Oral Study Presentation of the Prosigna™ Assay in Postmenopausal Node-Positive Breast Cancer at the 2013 Annual American Society of Clinical Oncology
NanoString Technologies Announces Oral Study Presentation of the Prosigna™ Assay in Postmenopausal Node-Positive Breast Cancer at the 2013 Annual American Society of Clinical Oncology   SEATTLE and CHICAGO | May 15, 2013 — NanoString Technologies, Inc., a privately held provider of life science
View HTML
Toggle Summary Study Results Show Prosigna™ Breast Cancer Prognostic Gene Signature Assay by NanoString Technologies Estimates Risk of Late Recurrence in Postmenopausal Hormone Receptor Positive Breast Cancer Patients
Study Results Show Prosigna™ Breast Cancer Prognostic Gene Signature Assay by NanoString Technologies Estimates Risk of Late Recurrence in Postmenopausal Hormone Receptor Positive Breast Cancer Patients   Positive Results from Two Studies of the PAM50-Based In Vitro Diagnostic Assay will be
View HTML
Toggle Summary NanoString Technologies Secures Option from The Broad Institute for Exclusive Worldwide License of Liver Cancer Gene Signature
NanoString Technologies Secures Option from The Broad Institute for Exclusive Worldwide License of Liver Cancer Gene Signature   SEATTLE, Wash. | April 17, 2013 – NanoString® Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic
View HTML
Toggle Summary NanoString Technologies Presents Positive Results from Multisite Analytical Validation Study of Prosigna™ Breast Cancer Prognostic Gene Signature Assay
NanoString Technologies Presents Positive Results from Multisite Analytical Validation Study of Prosigna™ Breast Cancer Prognostic Gene Signature Assay   PAM50-based In Vitro Diagnostic Run in Multiple Qualified Laboratories on the nCounter® System Demonstrated High Precision and Reproducibility
View HTML